Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
The OncoPPi network is a resource of experimentally determined physical protein-protein interactions that builds on cancer genomics for discovery and exploitation of cancer vulnerabilities.
MEDICI is a new computational method to predict the protein-protein interaction (PPI) essentiality which helps to prioritize PPIs for drug discovery.
Scientists at UTSW Medical Center identified Aurora Kinase A as a potential therapeutic target in NSCLCs with SMARCA4/BRG1 mutations
Emory researchers developed a new NanoLuc®-based protein-fragment complementation assay (NanoPCA) which allows the detection of novel protein-protein interactions.
FHCRC developed a tool which models gene centric dependencies across multiple genomic platforms. They demonstrated that this method could be used to identify genes essential to tumorigenesis in the pancreatic and lung adenocarcinoma patient cohorts from The Cancer Genome Atlas.
Expression profiles of 810 cancer lines and their response data to 368 small molecules from the Cancer Therapeutics Research Portal were analyzed to identify pathways with significant gene rewiring or differential gene dependency, between sensitive and non-sensitive lines.
A stromal protein signature for breast cancer (BCa) was created using tissue and matched lysates from two breast cancer patient datasets. Protein contents of the stroma were shown to be an extended phenotype not predicted by mRNA expression and could be utilized to subclassify BCa subtypes.
TARGET investigators report on the key role that loss of TP53 plays in the development of anaplasia in Wilms tumors and may reflect the risk of relapse and death in children with this disease.
Combination of complimentary genetic and proteomic approaches identify previously unreported regulators of β-catenin, define functional networks required for the survival of β-catenin-active cancers, and provide an experimental strategy that may be applied to define other signaling networks
Researchers at UTSW medical center identified nuclear export receptor XPO1 as a druggable target in certain types of KRAS mutant non-small cell lung cancers.